Capella

Anaptys reiterated its cash runway in the statement to disclose the licensing of ANB101 Biogen has a new rival for the BDCA2 space. AnaptysBio is picking up a distant potential challenger to the big biotech’s late-phase lupus candidate, paying Centessa Pharmaceuticals $7 million upfront for rights to a preclinical prospect that is still months away from being submitted for testing in humans.  BDCA2 is expressed exclusively on plasmacytoid dendritic cells. By binding to the antigen, antibodies can suppress the production of type I interferon and, in theory, improve outcomes in patients with diseases driven by the cytokine. Biogen reported midstage data on its drug candidate, litifilimab, in systemic lupus erythematosus last year and is running a phase 3 trial in the indication. Centessa picked up its BDCA2 program from Capella BioScience, one of the 10 biotechs it rolled up when it set up shop in 2021. Capella and Centessa have shared preclinical data on their lead BDCA2 candidate, CBS004, in systemic sclerosis, also known as scleroderma. Rather than take CBS004 into the clinic, Centessa, which is dissolving Capella and other U.K. businesses, has decided to offload the program to Anaptys for $7 million upfront. The fee includes a one-time cash payment of $3 million for manufactured and released GMP supply of CBS004, now renamed ANB101.  A $10 million milestone payment, in either cash or shares, is tied to the start of the first phase 3 trial.  In a statement, Anaptys CEO Daniel Faga outlined how ANB101 fits into the biotech’s strategy, explaining that it “specifically targets plasmacytoid dendritic cells, known to be key drivers of interferon secretion and antigen presentation” and complements its “immune cell modulators to drive differentiated clinical outcomes in systemic, heterogeneous autoimmune and inflammatory diseases.” Anaptys is adding ANB101 to its list of candidates that are set to join its two lead programs in the clinic. The biotech plans to file to study its CD122 antagonist ANB033 in humans in the first half of next year. An IND filing for ANB101 is slated for the second half of 2024. The candidates will sit alongside the PD-1 agonist rosnilimab and BTLA agonist ANB032 in Anaptys’ clinical-phase pipeline. Anaptys has started phase 2b trials of both candidates, in rheumatoid arthritis, ulcerative colitis and atopic dermatitis, in recent quarters, teeing up a series of data drops spanning from the end of next year through to the first half of 2026. Anaptys reiterated its cash runway in the statement to disclose the licensing of ANB101. The biotech still expects its money to fund operations through the end of 2026, giving it a shot at generating clinical data that drives up its share price before needing to seek additional funding.

The Bureau of Labor Statistics estimates that 200,000 nursing jobs will be open each year through at least 2031. Optum is teaming up with Capella University to launch a new educational program aimed at stemming the tide of the nurse shortage. The program is built on Optum's clinical expertise and care facilities along with Capella's capabilities as an accredited online university, according to an announcement. It will arm nursing students with the knowledge necessary to secure licensure and to step into leadership roles. Many of those in the program will be able to get hands-on experience at Optum's sites of care, the company said, and will have access to recruitment resources and job opportunities. “Optum and Capella University are working together to help address the critical need for qualified clinicians we all rely upon to keep us healthy and well,” said Kristy Duffey, chief nursing officer at Optum Health, in the release. “By bringing together our unique sets of skills and capabilities, we will be able to train the next generation of highly qualified nurse practitioners equipped to take on the health care challenges of tomorrow," Duffey said. The first offering under the partnership is a master's degree for adult-gerontology primary care nurse practitioners, according to the announcement. Students can begin to enroll now, with classes starting Oct. 9. Optum and Capella expect to launch a family nurse practitioner program down the line, according to the announcement. “Capella University is honored to partner with Optum to support the need for nurse practitioners,” said Dick Senese, president of Capella University, in the release. “Capella has a reputation of strong industry leadership in nursing education that we are thrilled to bring to this program as we expand our portfolio.” The Bureau of Labor Statistics estimates that 200,000 nursing jobs will be open each year through at least 2031. The issue is a major focus for industry leaders, with 94% of those surveyed in June on the matter naming the nursing shortage a priority.

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- NSR’s latest report, Global Satellite Manufacturing and Launch Markets, 11th Edition, sees post-pandemic rebound driven by constellations, innovative technologies, and new services offerings. Over the next 10 years, satellite manufacturing and launch order volumes reach nearly 24,700. Upcoming deadlines for international regulatory filings, strong investments from public and private investors, and the associated capacity influx by Non-GEO HTS will drive significant orders and launches through 2030. “With several ambitious and well-funded programs aiming to meet international deadlines under immense financial pressures, constellations will drive satellite manufacturing and launch volumes,” states NSR Principal Analyst and report lead author, Dallas Kasaboski. “While larger GEO satellites take on more complexity via software-defined and multi-mission payloads, other applications, like In-Orbit Servicing (IoS), Space Situational Awareness (SSA) and IoT drive additional market growth.” "The demand for new types of spacecraft and services in-orbit is increasing,” adds NSR Analyst and co-author Hussain Bokhari. “The drive for SSA continues, focusing on protection of assets via more satellites for Gov/Mil customers. Meanwhile, research and development satellites will help smaller players enter the market." Commercialization of crew and cargo flights also see a positive market outlook. Regardless of the forthcoming ISS decommissioning, Crew & Cargo missions dominate the Launch Market, generating the most revenue over the next decade, with private operators increasingly in the foreground. As governments and private companies pick up pace, the Beyond Earth and Deep Space Exploration markets will be greenfield opportunities. Upcoming deadlines for international regulatory filings, strong investments from private investors, and the associated capacity influx by Non-GEO HTS will drive significant levels of orders and launches through 2030. About the ReportNSR’s Global Satellite Manufacturing and Launch Markets, 11th Edition report (GSMLM11) offers the most comprehensive analysis available of the manufacturing and launch market in the next decade across 5 regions, 7 applications and 5 mass ranges. The report takes a deep dive into where sector demand is leading in terms of complexity, launch requirements, and operations. The report provides decision makers business-critical metrics into the traditional and NewSpace markets - their interactions, impacts, developments, and trends through to 2030. For additional information on this report, including a full table of contents, list of exhibits and executive summary, please visit or call NSR at +1-617-674-7743. Companies Profiled or Mentioned in this Report: Aerial & Maritime Ltd, Airbus, Aistech Space, Alpha Space Test and Research Alliance, Altius Space Machines, Amazon, Analytical Space, Spaceflight Systems, Applied Defense Solutions, Aquarian Space, Arctic Space Technologies, Ariane Group, Arianespace, Astra, Astranis Space Technologies Corp., Astro Digital, Astrobotic, Astrocast, Astrome, Astroscale, Atlas Space Operations, Audacy, AxelSpace, Ball Aerospace, Black Sky Inc., Blacksky, BlinkAstro, Blue Canyon Technologies, Blue Origin, Boeing, Bradford ECAPS, Bradford Space, C6 Launch Systems, Canadensys Aerospace Corp., Canadian Space Agency (CSA), Canon, Capella Space, Ceres Robotics, CGWIC, CisLunar Industries, ClearSpace SA, CNES, CNSA, Cobham AES Division, DARPA, Dauria Aerospace, Deep Space Systems, Deimos, DLR, D-Orbit, Dynetics Inc., EarthCube, Ericsson, ESA, European Commission, Eutelsat, ExactEarth, Exoanalytic Solutions, Firefly Aerospace Inc., Fleet Space Technologies, General Atomics, GeoOptics, GEOShare, GHGSat, Global Eagle, Global Star, GOMSpace, Goonhilly Earth Station, Groundspace, Hanwha Systems, HawkEye360, HEAD Aerospace Group, HeliosWire, Hera Systems, Hiber, Honeybee Robotics Spacecraft Mechanisms Corporation, HPE, Hughes, IBM, ICEYE, Icon Build, Infinite Orbits, Infostellar, Inmarsat, Intelsat, International Launch Services, Intuitive Machines, Iridium, ISISpace, ISpace China, ispace Inc., Israel Aerospace Industries, ISRO, KACST, Kepler Communications, Kineis, Kratos Defense & Space, KSAT, KUBOS, L3 Applied Defense Solutions, L3Harris Technologies, Lacuna Space, LaserLight Communications, LaserLight Solutions, Leafspace, Leidos Holdings, LEOCloud, LeoLabs, LeoSat, LeoStella, Lockheed Martin, Lockheed Martin Corporation, Loft Orbital, Los Alamos National Laboratory, Lyteloop, Masten Space Systems, Maxar, MDA, Microsoft, Mission Control Space Services, Mitsubishi Electric, Mitsubishi Heavy Industries, Mitsui & Co., Momentus, Momentus Space, Moon Express, Moonscape, Mynaric, Myriota, Nano Avionics, Nanoracks LLC, NASA, NASDA, Nokia, Northrop Grumman Corporation, NorthStar Earth & Space Inc., Novawurks, NPO Lavochkin, NSLComm, Okapi, OneWeb, OrbCOMM, Orbex, Orbit Fab, Orbital Insights, Orbits Edge, Paragon Space Development Corporation, Parsons, Phasor Solutions, Planet, PlanetIQ, Polaris Alpha, PredaSAR, Raytheon, Relativity Space, Rocket Lab, Roscosmos, Satellogic, Satlantis, Satsure, Saturn Satellite Networks, SES, Sierra Nevada Corporation, Sinclair Interplanetary, Sky and Space Global, Sky Perfect JSAT, Skyroot Aerospace, Skywatch, Space Data Association, Space Logistics, Space Systems Loral, Spacebit, Spaceflight, SpaceNav, SpaceX, Spire Global, SSC, Stratolaunch, Surrey Satellite Ltd. (SSL), Swarm Technologies, Swedish Space Corporation (SSC), Synspective, Teledyne Energy Systems, Telesat, Telespazio, Tethers Unlimited, Thales Alenia Space, The Boeing Company, Thuraya, Totum, Transcelestial Technologies, TransDigm, Trident Space, Turkish Space Agency (TUA), Tyvak Nano-Satellite System, U.S. DoD, U.S. Space Force, UAE Space Agency, UK Space Agency, Unibap, United Launch Alliance, UnseenLabs, Ursa, Urthecast, ViaSat, Virgin Galactic, Virgin Orbit, Vision Engineering Solutions, Voyager Space Holdings, We4sea, XpressSAR, Yamasa Co. About NSRNSR is the leading global market research and consulting firm focused on the satellite and space sectors, NSR’s global team, unparalleled coverage, and anticipation of trends with a high degree of confidence and precision than the competition is the cornerstone of all NSR offerings. First to market coverage and a transparent, dependable approach sets NSR apart as the key provider of critical insight to the satellite and space industries. Contact us at info@nsr.com to discuss how we can assist your business. Press Contact:Kristen Kloster-GradyNSR Marketing DirectorKKloster@NSR.com